Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
Sean D. Pokorney(Duke University), G. Larsen Kneller(Royal Perth Hospital), I. Niazi(Duke Medical Center), Subhash Banerjee(Janssen (United States)), Karen S. Pieper(Clinical Research Institute), Manesh R. Patel(Clinical Research Institute), Graeme J. Hankey, Daniel E. Singer(Harvard University), G. Mallis(Royal Perth Hospital), Jonathan P. Piccini, J. Anderson(Royal Perth Hospital), Rodolfo Sotolongo(Duke Medical Center), Erasmo de la Peña-Almaguer(Duke Medical Center), R. Ghanekar(Duke Medical Center), H. Snyder(Edinburgh Royal Infirmary), Brenda Peart(Duke Medical Center), Günter Breithardt(University Hospital Münster), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Keith A.A. Fox(University of Edinburgh), Wolfgang Herzog(Heidelberg University), Noel W. Bedwell(Stanford University), A. Flores, Susanna R. Stevens(Mayo Clinic), Martin Bilsker(Duke Medical Center), Scott D. Berkowitz(Bayer (United States)), Steven K. Krueger(University of Massachusetts Chan Medical School), Christopher C. Nessel(Johnson & Johnson (United States)), L. Yellen(Duke Medical Center), Kris Vijayaraghavan(Arizona Heart Institute), Brian Snoddy(Duke Medical Center), Daniel L. Lustgarten(Bayer (United States)), Ramtin Agah, Sri Sundaram(Janssen (United States)), Manish Modi(Imperial College London), Jonathan L. Halperin(Greenville College), C. Lee(Duke Medical Center), Graeme F. Woodworth(University of Maryland, Baltimore), Robert M. Califf(Duke Medical Center), Werner Hacke(Heidelberg University), L Levinson(Duke Medical Center), M Desantis(Duke Medical Center), G. Keith Bruce(Royal Perth Hospital), S Klein(Janssen (United States)), F. Whittier(Duke Medical Center), Dr.S Suresh(Bayer (United States)), M. Gelernt(Duke Medical Center), EFI LAVIE(Duke Medical Center), Richard C. Becker(Sabin Vaccine Institute), Steven Eisenberg(Janssen (United States)), John B. Moloney(Royal Perth Hospital)
Cited by 199
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k